Globe Life Inc. provides life and supplemental health insurance products to lower middle- and middle-income families in the United States through its subsidiaries. It operates in three segments: Life Insurance, Supplemental Health Insurance, and Investments. Its offerings include whole, term, and other life insurance, life insurance for children, Medicare supplement and limited-benefit supplemental health products, and final expense, accidental death, mortgage protection, and hospital insurance. Products are sold through direct-to-consumer channels, exclusive independent agents, general agency independent agents, and brokers. The company was formerly known as Torchmark Corporation and changed its name to Globe Life Inc. in August 2019. It was founded in 1900 and is headquartered in McKinney, Texas.
Globe Life Expands Buyback to $2.50 Billion Amid Weaker Margins
Globe Life Inc. has increased its share repurchase authorization to US$2.50 billion, declared a US$0.33 quarterly dividend for October 2026, and announced the retirement of director David A. Rodriguez for personal reasons. These capital return decisions and board changes came soon after Q2 2026 results highlighted weaker sales trends and underwriting margins despite analyst optimism. The enlarged buyback authorization sits alongside weaker Q2 2026 underwriting margins, raising fresh questions about how much of Globe Life's per share earnings progress will be driven by financial engineering versus underlying policy growth. Globe Life's narrative projects $7.4 billion revenue and $1.3 billion earnings by 2029, while more cautious analysts assume revenue of about US$7.2 billion and earnings near US$1.3 billion by 2029.
Globe Life Seen 4.8% Undervalued After Mixed Q2 Earnings
Globe Life is considered about 4.8% undervalued following its mixed second-quarter 2026 earnings, with a fair value estimate of $190.09 per share versus a recent close of $181. The company's earnings beat was offset by weaker sales trends and softer underwriting margins, while an expanded US$2.5 billion buyback authorization and a planned Bermuda reinsurance affiliate are expected to boost free cash flow and earnings per share by 2027. The stock has returned 16.74% over the past 90 days and 34.73% over the past year, and its current price-to-earnings ratio of 11.5 times is nearly in line with the US insurance sector average of 11.5 times.
Globe Life shares fall 6.1% despite raised 2026 guidance and expanded buybacks
Globe Life Inc. shares dropped 6.1% after the insurer raised its full-year 2026 net operating earnings guidance to US$15.55–US$15.95 per diluted share and expanded share repurchases. The upgraded outlook reflects higher life underwriting margins, stronger health premiums, and excess investment income, along with potential remeasurement gains of US$110 million to US$130 million from life and health assumption updates. Second-quarter revenue reached US$1,599.73 million with net income of US$287.75 million, and the company bought back 1,100,000 shares for US$175 million in the latest quarter under a program totaling about US$10.42 billion. The muted share price reaction after earnings highlights how concerns about long term fundamentals can still weigh on sentiment even when results improve.
Globe Life lifts 2026 EPS view to $15.55-$15.95 and boosts buyback plan to $670M-$700M
Globe Life raised its full-year 2026 net operating earnings per share guidance to a range of $15.55 to $15.95 and increased its planned share repurchases to between $670 million and $700 million. The updated outlook, provided during the company's second-quarter earnings call, compares with the prior quarter's EPS range of $15.40 to $15.90 and a previous buyback target of $560 million to $610 million. Co-Chairman and Co-CEO Frank Svoboda said total premium revenue growth is expected to be 6.5% to 7% for the year, with life premium revenue growing 2.5% to 3% and health premium revenue growing 14% to 16%. Executive VP and CFO Thomas Kalmbach noted the guidance reflects potential remeasurement gains of $110 million to $130 million from third-quarter assumption updates, and he anticipates third-quarter life underwriting margin will be in the range of 52% to 53% of premium. During the second quarter, the company repurchased about 1.1 million shares for $175 million, and management indicated the higher buyback pace is supported by increased parent liquidity, including an expansion of a term loan from $250 million to $450 million.
Globe Life will announce its earnings results this Wednesday afternoon. The insurance holding company met revenue expectations last quarter with $1.56 billion, up 5.4% year on year, but missed analysts' estimates for book value per share and EPS. For the upcoming report, the market expects revenue to grow 6.2% year on year, an improvement from the 3.2% increase in the same quarter last year. Analysts have generally reconfirmed their estimates over the last 30 days. Peers Travelers and W. R. Berkley have already reported Q2 results, with Travelers posting flat year-on-year revenue and missing expectations by 0.9%, while W. R. Berkley's revenue rose 1.2% and fell short of estimates by 1.4%. Globe Life shares are up 6.4% over the last month, heading into earnings with an average analyst price target of $188.55 compared to the current share price of $183.14.
Globe Life Could Be 4% Above Fair Value After Financing Reset
Globe Life has amended and restated its credit and term loan agreements, extending maturities, increasing borrowing capacity, and shifting key administrative roles to Wells Fargo. The stock is trading at $179.13, about 4% above a widely followed fair value estimate of $172.10, implying a modest premium. The planned establishment of a Bermuda reinsurance affiliate is expected to significantly boost parent company free cash flow and financial flexibility by 2027 and beyond, supporting greater share repurchases or strategic investments. However, heavy reliance on traditional agents and ongoing regulatory investigations could pressure growth assumptions and limit capital returns. Globe Life's 11.8x price-to-earnings ratio is below the US insurance industry average of 12.3x and well below the 19x peer average, but slightly above its 11.5x fair ratio.
Globe Life Q2 2026 Earnings Preview: EPS Expected to Rise 11.9%
Globe Life is set to report second-quarter 2026 earnings, with analysts forecasting diluted earnings per share of $3.66, an 11.9% increase from $3.27 in the same quarter last year. The McKinney, Texas-based insurer, valued at $13.9 billion, has beaten EPS estimates in two of the past four quarters while missing in the other two. For the full fiscal year 2026, EPS is projected at $15.64, up 7.7% from $14.52 in fiscal 2025, with further growth to $16.64 expected in fiscal 2027. Globe Life stock has surged 44.7% over the past 52 weeks, outperforming the S&P 500's 19.9% gain and the State Street Financial Select Sector SPDR ETF's 3.4% rise. Analysts hold a Moderate Buy rating on the stock, with an average price target of $177.50 and a Street-high target of $215, implying a 19.9% upside.
Globe Life Stock Surges 26.2% in Six Months, But Analysts Remain Cautious
Globe Life shares have climbed 26.2% over the past six months to $178.90, outperforming the S&P 500 by 19.4 percentage points. Despite the rally, analysts at StockStory are not recommending the stock, citing tepid 4.8% annualized revenue growth over five years and soft net premiums earned growth of 4.9% annually over the past two years. Book value per share has accelerated to 20.8% annual growth over two years, reaching $78.12, but the stock trades at 2.1 times forward price-to-book. The analysts suggest there are better investment opportunities elsewhere.
Globe Life Executive Exercises Options, Sells Shares Amid 6.3% Sales Growth Outlook
In June 2026, Globe Life executive Rebecca E. Zorn exercised 2,000 stock options and sold 2,000 common shares at prices between US$169.70 and US$170.41. Analysts maintain a positive outlook on the insurer, highlighting an expected 6.3% sales growth rate for 2026 and a favorable Zacks Rank #2. Despite a recent quarter that missed EPS and book value per share estimates, Globe Life has been repeatedly cited as a top sales-growth name, underscoring confidence in its underlying business momentum. The company's narrative projects US$6.8 billion in revenue and US$1.3 billion in earnings by 2028, requiring 5.1% yearly revenue growth. Investors should also weigh ongoing DOJ and SEC investigations that could materially affect the company.
Life Insurance Stocks Q1 Results: Globe Life Revenue Up 5.4%, Primerica Leads, Brighthouse Lags
Life insurance stocks tracked by StockStory reported a slower first quarter, with aggregate revenues beating analysts' consensus estimates by 3.1%. Globe Life posted revenue of $1.56 billion, up 5.4% year on year and in line with expectations, but missed book value per share and EPS estimates. Primerica was the best performer with revenue of $872.3 million, up 8.6% year on year and beating expectations by 1.9%, along with beats on book value per share and EPS. Brighthouse Financial was the weakest, with revenue of $2.10 billion, down 2.7% year on year and missing expectations by 4.8%, alongside significant misses on book value per share and EPS. Unum Group reported revenue of $2.93 billion, down 11.3% year on year and missing expectations by 5.2%, while Horace Mann Educators posted revenue of $429.3 million, up 3.1% year on year but 3.1% below expectations. Share prices of the group have been resilient, up 6.3% on average since the latest earnings results.
Zacks.com highlights CACI International, Globe Life, and Knight-Swift Transportation as sales growth picks
Zacks.com featured CACI International, Globe Life, and Knight-Swift Transportation Holdings as stocks with solid sales growth in a resilient market. CACI International's expected sales growth rate for fiscal 2027 is 10.6%, Globe Life's expected sales growth rate for 2026 is 6.3%, and Knight-Swift Transportation's sales are expected to rise 7.1% in 2026. All three stocks carry a Zacks Rank of 2. The article emphasizes that sales growth provides a reliable indicator of business momentum and can support stronger profitability through operating leverage.
CACI · Capital · Positive Highlighted as having strong expected sales growth (10.6% for FY2027) and a Zacks Rank of 2, indicating positive analyst sentiment.
GL · Capital · Positive Highlighted as having strong expected sales growth (6.3% for 2026) and a Zacks Rank of 2, indicating positive analyst sentiment.
KNX · Capital · Positive Highlighted as having strong expected sales growth (7.1% for 2026) and a Zacks Rank of 2, indicating positive analyst sentiment.
United States